This final preview featuring the thoughts and anticipations of Louise Campbell and Roger Green explores the idea of harnessing technology to maximize the utility of databases in the effort of identifying patients.
This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.
The podcast celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. This conversation offers observations around the new NICE guidance that supports FibroScan use in primary care settings. The group ventures on to discuss the effects of socioeconomic status on access to improved liver health.
The podcast celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. This conversation focuses on the increasing incidence of NAFLD/NASH among adolescents. The group explores ideas around why this is happening and what to do about it.
The podcast celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. This conversation reviews the unique ways different organizations from across the world have interacted with and shown support for #NASHDay 2023.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This final conversation addresses a closing question around the future of FibroScan and how NICE will have progressed on the issue over the next 18 months.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation offers stimulating ideas around best ways to implement community screening.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation speculates on the value and accuracy of FAST and other tests. The group considers the importance of collecting data and what impact the guidance and experience in the UK will have for onlooking systems.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation focuses on the role of the British Liver Trust in this process and the importance of data collection for quality assurance.
The episode celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. Each speaks to what the day means to them and the group explores how the community is taking action to step up to a public health epidemic.
